$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000162828016018534 Filed on August 04, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$774.0K	$309.0K	$3.440M
YoY Change	-80.96%	-91.02%	89.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.720M	$23.77M	$7.660M
YoY Change	-51.75%	210.31%	327.93%
% of Gross Profit
Research & Development	$15.74M	$15.22M	$9.690M
YoY Change	-3.77%	57.02%	4.22%
% of Gross Profit
Depreciation & Amortization	$291.0K	$252.0K	$147.0K
YoY Change	90.2%	71.43%	-1.34%
% of Gross Profit
Operating Expenses	$19.75M	$195.6M	$17.86M
YoY Change	-68.25%	994.94%	58.98%
Operating Profit	-$18.98M	-$195.2M	-$14.42M
YoY Change	-67.36%	1254.01%	53.03%
Interest Expense	$0.00	$0.00	-$470.0K
YoY Change	-100.0%	-100.0%	-114.07%
% of Operating Profit
Other Income/Expense, Net	-$620.0K	$384.0K	-$466.0K
YoY Change	-104.44%	-182.4%
Pretax Income	-$19.60M	-$194.9M	-$14.89M
YoY Change	-55.65%	1209.04%	144.84%
Income Tax	$0.00	-$64.86M	$0.00
% Of Pretax Income
Net Earnings	-$19.60M	-$130.0M	-$14.89M
YoY Change	-32.39%	773.3%	144.8%
Net Earnings / Revenue	-2531.65%	-42071.2%	-432.73%
Basic Earnings Per Share
Diluted Earnings Per Share	-$365.3K	-$2.466M	-$274.4K
COMMON SHARES
Basic Shares Outstanding	54.80M shares	54.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$149.7M	$165.3M	$207.2M
YoY Change	-23.66%	-20.22%	76.79%
Cash & Equivalents	$26.63M	$42.97M	$207.2M
Short-Term Investments	$123.1M	$122.3M	$0.00
Other Short-Term Assets	$1.500M	$2.000M	$1.800M
YoY Change	25.0%	11.11%	350.0%
Inventory
Prepaid Expenses
Receivables	$395.0K	$456.0K	$6.332M
Other Receivables	$200.0K	$100.0K	$0.00
Total Short-Term Assets	$151.8M	$168.1M	$215.7M
YoY Change	-24.09%	-22.08%	82.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.086M	$3.944M	$2.036M
YoY Change	77.65%	93.71%	19.76%
Goodwill	$162.5M	$162.5M	$156.1M
YoY Change		4.14%
Intangibles	$196.3M	$196.3M	$390.0M
YoY Change		-49.66%
Long-Term Investments	$0.00	$0.00	$10.00M
YoY Change	-100.0%	-100.0%	-18.03%
Other Assets
YoY Change
Total Long-Term Assets	$362.9M	$362.8M	$558.1M
YoY Change	-30.56%	-35.0%	3915.24%
TOTAL ASSETS
Total Short-Term Assets	$151.8M	$168.1M	$215.7M
Total Long-Term Assets	$362.9M	$362.8M	$558.1M
Total Assets	$514.7M	$530.9M	$773.8M
YoY Change	-28.77%	-31.4%	485.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.100M	$1.700M	$2.800M
YoY Change	-27.59%	-39.29%	55.56%
Accrued Expenses	$4.800M	$5.700M	$3.800M
YoY Change	11.63%	50.0%	90.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.392M	$10.08M	$16.13M
YoY Change	-39.19%	-37.49%	-1.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$8.300M	$8.000M	$13.20M
YoY Change	-38.97%	-39.39%	25.71%
Total Long-Term Liabilities	$8.300M	$8.000M	$13.20M
YoY Change	-38.97%	-39.39%	25.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.392M	$10.08M	$16.13M
Total Long-Term Liabilities	$8.300M	$8.000M	$13.20M
Total Liabilities	$98.11M	$99.54M	$185.3M
YoY Change	-41.88%	-46.29%	588.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$432.5M	-$412.9M	-$232.7M
YoY Change		77.39%
Common Stock	$864.4M	$861.1M	$821.7M
YoY Change		4.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$416.6M	$431.3M	$588.5M
YoY Change
Total Liabilities & Shareholders Equity	$514.7M	$530.9M	$773.8M
YoY Change	-28.77%	-31.4%	485.78%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$19.60M	-$130.0M	-$14.89M
YoY Change	-32.39%	773.3%	144.8%
Depreciation, Depletion And Amortization	$291.0K	$252.0K	$147.0K
YoY Change	90.2%	71.43%	-1.34%
Cash From Operating Activities	-$14.71M	-$16.80M	-$16.67M
YoY Change	482.19%	0.8%	108.13%
INVESTING ACTIVITIES
Capital Expenditures	$168.0K	$954.0K	$383.0K
YoY Change	-71.48%	149.09%	55.69%
Acquisitions
YoY Change
Other Investing Activities	-$710.0K	-$84.44M	-$9.950M
YoY Change	-95.86%	748.64%	-76.86%
Cash From Investing Activities	-$880.0K	-$85.39M	-$10.33M
YoY Change	-95.04%	726.89%	-76.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00	$2.000K
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$76.00K	$446.0K	$960.0K
YoY Change	-34.48%	-53.54%	310.26%
NET CHANGE
Cash From Operating Activities	-$14.71M	-$16.80M	-$16.67M
Cash From Investing Activities	-$880.0K	-$85.39M	-$10.33M
Cash From Financing Activities	$76.00K	$446.0K	$960.0K
Net Change In Cash	-$15.52M	-$101.8M	-$26.04M
YoY Change	-22.97%	290.78%	-48.96%
FREE CASH FLOW
Cash From Operating Activities	-$14.71M	-$16.80M	-$16.67M
Capital Expenditures	$168.0K	$954.0K	$383.0K
Free Cash Flow	-$14.88M	-$17.76M	-$17.05M
YoY Change	377.54%	4.13%	106.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	0	USD
	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	0	USD
CY2015Q2	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	0	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
CY2015Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2331000	USD
CY2016Q2	abus	Accrued Payroll Current AccruedPayrollCurrent	347000	USD
CY2015Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2358000	USD
CY2016Q2	abus	Accrued Research And Development AccruedResearchAndDevelopment	4323000	USD
	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	2676000	USD
	abus	Adjustmentsto Additional Paidin Capital Reclassificationof Equityto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalReclassificationofEquitytoLiabilityStockOptionAwards	3243000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2866000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	341000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	246000	USD
CY2015Q4	abus	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	2.33
CY2016Q2	abus	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	1.53
	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	-351000	USD
CY2016Q2	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	252000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	496000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-801000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-329000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9323000	CAD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2015Q2	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
CY2016Q2	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	1000000	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2015Q1	abus	Potential Proceeds Of Additional Shares Authorized PotentialProceedsOfAdditionalSharesAuthorized	22781000	USD
CY2015Q1	abus	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	142175000	USD
	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2016Q2	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	2.24
CY2016Q1	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	3.61
	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue	2.20
CY2016Q2	abus	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Fair Value Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingFairValuePrice	2.08
CY2016Q1	abus	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Fair Value Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingFairValuePrice	3.33
CY2016Q2	abus	Stock Option Liability Fair Value Disclosure StockOptionLiabilityFairValueDisclosure	1312000	USD
CY2016Q1	abus	Stock Option Liability Fair Value Disclosure StockOptionLiabilityFairValueDisclosure	1909000	USD
CY2016Q2	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	us-gaap	Depreciation Depreciation	469000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54796741	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8827000	USD
CY2016Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7753000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2610000	USD
CY2016Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1744000	USD
CY2015Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1008000	USD
CY2016Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	456000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1008000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	456000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	640000	USD
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	568000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9729000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10177000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30206000	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32817000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29278000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6399738	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5488162	shares
CY2015Q4	us-gaap	Assets Assets	712291000	USD
CY2016Q2	us-gaap	Assets Assets	530861000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	183882000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	168085000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	191374000	USD
CY2016Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	155183000	USD
CY2015Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	361000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9656000	USD
CY2016Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
CY2015Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	252000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	496000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7497000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7993000	USD
CY2015Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	324000	USD
CY2016Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72187000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	232276000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	207205000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166779000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144772000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42970000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	166779000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	42970000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25071000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	135018000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-101802000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-123809000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	379500	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	201000	shares
CY2015Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54570691	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54796741	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54570691	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54796741	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	834240000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	861148000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11663000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32826000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-130000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-145874000	USD
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	2310000	USD
	us-gaap	Contracts Revenue ContractsRevenue	5830000	USD
CY2016Q2	us-gaap	Contracts Revenue ContractsRevenue	32000	USD
	us-gaap	Contracts Revenue ContractsRevenue	139000	USD
CY2015Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	0	USD
CY2016Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	1312000	USD
CY2015Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-64864000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-64864000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	1081000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	711000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	868000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	711000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	213000	USD
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	146324000	USD
CY2016Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	81460000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	147000	USD
	us-gaap	Depreciation Depreciation	267000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	252000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.47
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.80
CY2015Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	967000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-340000	USD
CY2016Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-51000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2956000	USD
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7M6D
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5M04D
CY2015	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.4907
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.6737
CY2015	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0048
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0054
CY2015Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2024000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	801000	USD
CY2016Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	168000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	329000	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2571000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4467000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	33000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2975000	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2639000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4418000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-51000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2956000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7662000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10378000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23766000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30985000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	162514000	USD
CY2016Q2	us-gaap	Goodwill Goodwill	162514000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	156324000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	156324000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14886000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-26875000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-194864000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-210738000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-64864000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-64864000	USD
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	246000	USD
CY2016Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	148000	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7351000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5343000	USD
CY2016Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	42000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1074000	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1738000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4624000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	298000	USD
CY2016Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	573000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	435000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	679000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	847000	USD
CY2015Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	519000	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	196318000	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	81000	USD
CY2016Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	116000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-552000	USD
CY2015Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	334000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-957000	USD
CY2016Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-213000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-370000	USD
CY2015Q2	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2016Q2	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
CY2015Q2	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-1304000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-178000	USD
CY2016Q2	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	352642000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	283000	USD
CY2015Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	14525000	USD
CY2016Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	112213000	USD
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	297000	USD
CY2016Q2	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	265000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	164612000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	99537000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	712291000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	530861000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10578000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10084000	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	8380000	USD
CY2016Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	9613000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	1130000	USD
	us-gaap	Licenses Revenue LicensesRevenue	2292000	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	277000	USD
	us-gaap	Licenses Revenue LicensesRevenue	773000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	10070000	USD
CY2016Q2	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	960000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143780000	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	446000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	561000	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10327000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27219000	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85393000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-98975000	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16671000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35641000	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16804000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28351000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-14886000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26875000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-130000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-145874000	USD
CY2015Q2	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	381618000	USD
CY2016Q2	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-466000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5551000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	384000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4487000	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	17860000	USD
	us-gaap	Operating Expenses OperatingExpenses	40548000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	195557000	USD
	us-gaap	Operating Expenses OperatingExpenses	216137000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14420000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32426000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-195248000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-215225000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	591000	USD
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	506000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3223000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5951000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2015Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	9944000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-27419000	USD
CY2016Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	84439000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	97745000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9700000	USD
CY2015Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	383000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	524000	USD
CY2016Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	954000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1230000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1196000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2043000	USD
CY2015Q2	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	25000	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	25000	USD
CY2016Q2	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151875000	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142177000	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	939000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1559000	USD
CY2016Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	116000	USD
CY2015Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	19000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	44000	USD
CY2016Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12912000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14121000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3183000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3944000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9690000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20247000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15215000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28359000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266985000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-412859000	USD
CY2015Q2	us-gaap	Revenues Revenues	3440000	USD
	us-gaap	Revenues Revenues	8122000	USD
CY2016Q2	us-gaap	Revenues Revenues	309000	USD
	us-gaap	Revenues Revenues	912000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9778
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8277
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0086
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0088
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	5000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	23833	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.94
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1125000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	604000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	288000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	718333	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	694500	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	718333	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.23
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.24
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.64
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.28
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.87
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.46
CY2015Q1	us-gaap	Share Price SharePrice	20.25
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P30D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	288000	USD
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	60646	shares
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	134000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	161000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	73354	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y7M
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	14525000	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	122340000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7500000	shares
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	692000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	116000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	547679000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	431324000	USD
CY2015Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2016Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	883000	USD
CY2016Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	308000	USD
CY2014Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5099000	USD
CY2015Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	3606000	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	883000	USD
CY2016Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	308000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54255804	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42297517	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52716059	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52052165	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (“HBV”), a disease of the liver caused by hepatitis B virus (“HBV”). </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-018534-index-headers.html	Edgar Link	pending
0001628280-16-018534-index.html	Edgar Link	pending
0001628280-16-018534.txt	Edgar Link	pending
0001628280-16-018534-xbrl.zip	Edgar Link	pending
abus-20160630.xml	Edgar Link	completed
abus-20160630.xsd	Edgar Link	pending
abus-20160630_cal.xml	Edgar Link	unprocessable
abus-20160630_def.xml	Edgar Link	unprocessable
abus-20160630_lab.xml	Edgar Link	unprocessable
abus-20160630_pre.xml	Edgar Link	unprocessable
arbutusq22016.htm	Edgar Link	pending
exhibit101q22016.htm	Edgar Link	pending
exhibit102q22016.htm	Edgar Link	pending
exhibit103q22016.htm	Edgar Link	pending
exhibit311q22016.htm	Edgar Link	pending
exhibit312q22016.htm	Edgar Link	pending
exhibit321q22016.htm	Edgar Link	pending
exhibit322q22016.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
researchprograms.jpg	Edgar Link	pending
revisedhbvpipelinea02.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2016 Q3 Form 10-Q Financial Statement

#000162828016018534 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2016 Q3 Form 10-Q Financial Statement

#000162828016018534 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus